Evidence map›Paper›PMID 34135506›Full record

Trial reportNature2021

ctDNA guiding adjuvant immunotherapy in urothelial carcinoma.

Thomas Powles, Zoe June Assaf, Nicole Davarpanah, Romain Banchereau, Bernadett E Szabados, Kobe C Yuen, Petros Grivas, Maha Hussain, Stephane Oudard, Jürgen E Gschwend and 17 more

Abstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Nature, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 352 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
352citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

352 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Progress in immunotherapy for resectable head and neck squamous cell carcinoma.Medical oncology (Northwood, London, England) · 2025
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Accelerating Drug Development in Hormone-Naïve Prostate Cancer through Multimodal Therapy Strategies: The MetaCURE Phase 2 Randomized Clinical Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Trial
  18. Trial
  19. Article
  20. Article

292 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

27 authors.

Thomas Powles *Barts Cancer Institute, Queen Mary University of London ECMC, Barts Health, London, UK. thomas.powles1@nhs.net.ORCID http://orcid.org/0000-0001-7760-4724
Zoe June Assaf *Roche/Genentech, South San Francisco, CA, USA.
Nicole DavarpanahRoche/Genentech, South San Francisco, CA, USA.
Romain BanchereauRoche/Genentech, South San Francisco, CA, USA.
Bernadett E SzabadosBarts Cancer Institute, Queen Mary University of London, London, UK.
Kobe C YuenRoche/Genentech, South San Francisco, CA, USA.
Petros GrivasUniversity of Washington, Seattle, WA, USA.
Maha HussainRobert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA.
Stephane OudardGeorges Pompidou European Hospital, University of Paris, Paris, France.
Jürgen E GschwendRechts der Isar Medical Center, Department of Urology, Technical University Munich, Munich, Germany.
Peter AlbersHeinrich-Heine University Düsseldorf, Medical Faculty, Department of Urology, University Hospital Düsseldorf, Düsseldorf, Germany.
Daniel CastellanoUniversity Hospital 12 de Octubre, Medical Oncology Department CIBER-ONC, Madrid, Spain.
Hiroyuki NishiyamaDepartment of Urology, Faculty of Medicine University of Tsukuba, Ibaraki, Japan.
Siamak DaneshmandUSC Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
Shruti SharmaNatera, Inc, San Carlos, CA, USA.
Bernhard G ZimmermannNatera, Inc, San Carlos, CA, USA.
Himanshu SethiNatera, Inc, San Carlos, CA, USA.
Alexey AleshinNatera, Inc, San Carlos, CA, USA.
Maurizio PerdicchioF. Hoffmann-La Roche Ltd, Basel, Switzerland.
Jingbin ZhangHoffmann-La Roche Ltd, Mississauga, Ontario, Canada.
David S ShamesRoche/Genentech, South San Francisco, CA, USA.
Viraj DegaonkarRoche/Genentech, South San Francisco, CA, USA.
Xiaodong ShenRoche/Genentech, South San Francisco, CA, USA.
Corey CarterRoche/Genentech, South San Francisco, CA, USA.
Carlos BaisRoche/Genentech, South San Francisco, CA, USA.
Joaquim BellmuntBeth Israel Deaconess Medical Center, PSMAR-IMIM Lab, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0003-2328-3421
Sanjeev MariathasanRoche/Genentech, South San Francisco, CA, USA. mariathasan.sanjeev@gene.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Minimally invasive approaches to detect residual disease after surgery are needed to identify patients with cancer who are at risk for metastatic relapse. Circulating tumour DNA (ctDNA) holds promise as a biomarker for molecular residual disease and relapse

Indexed as

ImmunotherapyAdjuvants, PharmaceuticAntibodies, Monoclonal, HumanizedBiomarkers, TumorCirculating Tumor DNAGene Expression Regulation, NeoplasticHumansKaplan-Meier EstimateNeoplasm Recurrence, LocalPostoperative CarePrognosisRecurrenceSurvival AnalysisUrinary Bladder NeoplasmsAdjuvants, PharmaceuticAntibodies, Monoclonal, HumanizedatezolizumabBiomarkers, TumorCirculating Tumor DNA

Identifiers

PMID34135506

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.